SREBF1 and fatty liver disease: For example, neddylation of SREBP1c competes with its ubiquitination and promotes hepatic steatosis, while treatment with the neddylation-inhibitor Pevonedistat (MLN4924) decreased high fat diet-induced hepatic steatosis by decreasing SREBP1c and hepatic triglycerides [73].